title: Hypercoagulability in Kidney Transplant Recipients.
abstract: Thrombosis remains an important complication after kidney transplantation. Outcomes for graft and deep vein thrombosis are not favorable. The majority of early kidney transplant failure in adults is due to allograft thrombosis. Risk stratification, early diagnosis, and appropriate intervention are critical to the management of thrombotic complications of transplant. In patients with end-stage renal disease, the prevalence of acquired risk factors for thrombosis is significantly high. Because of hereditary and acquired risk factors, renal transplant recipients manifest features of a chronic prothrombotic state. Identification of hereditary thrombotic risk factors before transplantation may be a useful tool for selecting appropriate candidates for thrombosis prophylaxis immediately after transplantation. Short-term anticoagulation may be appropriate for all patients after kidney transplantation.
authors.affiliation: 1 Division of Nephrology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI. 2 Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR. 3 Portland VA Medical Center, Portland, Oregon. 4 Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR.
authors.forename: Sandesh
authors.initials: S
authors.lastname: Parajuli
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Lockridge
authors.forename: Eric D
authors.initials: ED
authors.lastname: Langewisch
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Norman
authors.forename: Jody L
authors.initials: JL
authors.lastname: Kujovich
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects / Q000235:genetics; D025861:Blood Coagulation Disorders, Inherited / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000175:diagnosis / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects*; D010641:Phenotype; D018570:Risk Assessment; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D013927:Thrombosis / Q000097:blood / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D066027:Transplant Recipients; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents